Stock Events

Stock Events

Molecular Partners 

$3.80
15
+$0.20+5.56% Tuesday 18:28

Statistics

Day High
2.55
Day Low
2.55
52W High
4.85
52W Low
2.25
Volume
100
Avg. Volume
77
Mkt Cap
142.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.69
-0.56
-0.44
-0.31
Expected EPS
-0.432985
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-77.74MNet Income

Analyst Ratings

13.00Average Price Target
The highest estimate is 13.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLLCF. It's not an investment recommendation.
UBS Group
5
UBSG.SW
Nestle SA
4
NESN.SW
Novartis
4
NOVN.SW
Zurich Insurance Group
4
ZURN.SW

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the biotech space, focusing on similar therapeutic areas as Molecular Partners, including ophthalmology and oncology.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotechnology company with a broad portfolio that includes treatments in areas where Molecular Partners is active, making them direct competitors in drug development.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals operates in the biotech sector, focusing on creating transformative medicines in areas like cystic fibrosis, where Molecular Partners could potentially compete.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is known for its work in antiviral drugs and other therapeutic areas that overlap with Molecular Partners’ research interests, particularly in oncology and infectious diseases.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurological diseases and has ventured into areas that could compete with Molecular Partners’ therapeutic targets.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel area of science that could compete with Molecular Partners’ DARPin platform in targeting diseases at the genetic level.
Moderna
MRNA
Mkt Cap25.28B
Moderna is known for its mRNA technology platform, which competes in the broader biotech space for developing innovative therapies, including potential overlaps in therapeutic areas with Molecular Partners.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on rare genetic diseases, a field where Molecular Partners could potentially introduce competing therapeutic solutions.
Novartis
NVS
Mkt Cap286.78B
Novartis is a large pharmaceutical company with a wide range of products that compete across various therapeutic areas, including those targeted by Molecular Partners, due to its size and breadth of research.

About

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Show more...
CEO
Patrick Amstutz
Employees
134
Country
Switzerland
ISIN
CH0256379097
WKN
000A12DEH

Listings

STU
DE
6ML0.STU
STU
DE
6ML.STU
BOATS
BOATS
MOLN.BOATS
MU
DE
6ML.MU

0 Comments

Share your thoughts

FAQ

What is Molecular Partners stock price today?▼
The current price of MLLCF is $3.80 USD — it has increased by +5.56% in the past 24 hours. Watch Molecular Partners stock price performance more closely on the chart.
What is Molecular Partners stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Molecular Partners stocks are traded under the ticker MLLCF.
Is Molecular Partners stock price growing?▼
MLLCF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Molecular Partners has showed a -9.95% decrease.
What is Molecular Partners market cap?▼
Today Molecular Partners has the market capitalization of 142.54M
When is the next Molecular Partners earnings date?▼
Molecular Partners is going to release the next earnings report on August 25, 2026.
What were Molecular Partners earnings last quarter?▼
MLLCF earnings for the last quarter are -0.44 USD per share, whereas the estimation was -0.43 USD resulting in a -2.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Molecular Partners revenue for the last year?▼
Molecular Partners revenue for the last year amounts to 0 USD.
What is Molecular Partners net income for the last year?▼
MLLCF net income for the last year is -77.74M USD.
How many employees does Molecular Partners have?▼
As of August 21, 2026, the company has 134 employees.
In which sector is Molecular Partners located?▼
Molecular Partners operates in the Health & Wellness sector.
When did Molecular Partners complete a stock split?▼
Molecular Partners has not had any recent stock splits.
Where is Molecular Partners headquartered?▼
Molecular Partners is headquartered in Schlieren, Switzerland.